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Abstract S16 Table 1 Diagnostic performance of %VLFI and ODI >3%
for detection of SDB in CHF patients
%VLFI ODI>3%
Sensitivity 0.53 0.97
Specificity 0.44 0.32
Positive predictive value 0.45 0.53
Negative predictive value 0.51 0.94
Positive likelihood ratio 0.94 1.42
Negative likelihood ratio 1.08 0.08
Area under receiver operating characteristic curve 0.49 0.92
Funding This study was funded by the British Heart Foundation.
S17 A PILOT STUDY OF THE PREVALENCE OF SLEEP
DISORDERED BREATHING (SDB) AND NOCTURNAL
HYPOXIA IN SYMPTOMATIC ADULTS WITH SICKLE CELL
DISEASE (SCD) AND ITS RELATIONSHIP WITH DISEASE
SEVERITY
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Introduction There are few effective therapies available for the long-
term management of the cardiac and renal sequelae of SCD. Iden-
tifying reversible factors, which exacerbate disease severity, would
facilitate development of new therapies or novel applications of
established treatments. Nocturnal hypoxia (NH) merits inves-
tigation as a disease modulating factor as it is established that
hypoxia promotes polymerisation of sickle haemoglobin and this is
reversible with oxygen therapy (Noguchi et al, 1993). Although NH
is common in children with SCD and is associated with poor
outcome, similar data for adults with SCD are lacking. This is
the ﬁrst study to determine the prevalence of OSA and NH and
quantify the severity of NH in adults with SCD. In addition, we
investigated the correlation between the degree of NH and organ
dysfunction.
Method Patients attending SCD clinic had an Epworth sleepiness
score performed. Patients with either an ESS $10 or symptoms
suggestive of SDB were offered nocturnal oximetry. Nocturnal
oximetry ﬁndings were objectively scored and compared with the
detailed clinical datasets collected at regular clinic attendances. OSA
was deﬁned as 4% oxygen desaturation index (4% ODI) of >10
events/h and NH was deﬁned as >30% total sleep time (TST) with
SpO2 <90%.
Results 93 patients were screened. 34 had ESS $10 or clinical
symptoms suggestive of SDB. 22 underwent nocturnal oximetry;
mean ESS 1264, clinic SpO2 9664%, 4% ODI 866 events/h,
nocturnal SpO2 9164%, %TST SpO2 <90% 43641%. Prevalence of
OSA and NH was 59%. The degree of nocturnal hypoxia was
correlated with urine protein:creatinine (r¼0.35, p¼0.02), elevated
pulmonary artery systolic pressure (r¼0.71; p¼0.0001) and prev-
alence of priapism (p¼0.004). There was no difference detected in
frequency of painful crises or hospital admission in patients with
signiﬁcant NH compared to those without NH.
Conclusion This small pilot study showed that OSA and NH had a
prevalence of 59% in symptomatic adult SCD patients. These data
have demonstrated a correlation between the severity of nocturnal
hypoxia and pulmonary hypertension, renal impairment and
priapism. These observations have not previously been reported.
The strength of these correlations could suggest a causal relation-
ship, although this needs to be conﬁrmed in a larger prospective
trial. Future studies should investigate the relationship between
OSA, nocturnal hypoxia and organ dysfunction and need to be
focussed on interventions such as nocturnal oxygen and continuous
positive airway pressure.
New assessments in cystic fibrosis
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We will be undertaking a phase IIB clinical trial of repeated applica-
tion of liposome-based gene therapy over a one year period in
approximately 100 CF patients (Multidose Trial). In preparation for
this, we sought to address two key questions. Firstly, could we deﬁne
the optimal set of patients in which the therapy could both be
delivered (good access to the airways via nebulisation), and in whom
any therapeutic effect was measurable (one or more abnormal
measures of lung disease). Secondly, in this set of ‘can deliverdcan
measure’ patients, which biomarker(s) could be powered to be the
primary outcomemeasure for the trial. To address both questions, we
undertook a study (Run-in), cross-sectionally assessing ‘can deliver ’
and longitudinally assessing a large set of candidate biomarkers for
‘can measure’.192 patients from age 10 upwards, with FEV1 >40%
were enrolled at two clinical centres; 154 of these remained in the
study after four visits spaced at approximately 4e5 month intervals.
Biomarkers assessed cross-sectionally included radionucleotide
deposition scans, CT and mucocilary clearance. Longitudinal
biomarkers included a large series of serum, sputum and exhaled
breath inﬂammatory markers, lung physiology, exercise-related
assays and quality of life assessment. 12 patients were judged too
severe for adequate delivery and were excluded. A shortlist of 4
biomarkers was generated based on a) showing a CF/non-CF differ-
ence, b) response to course of intravenous antibiotics, and c) coef-
ﬁcients of variation. These four were matched against the remaining
142 patients, and a further seven patients excluded in whom none of
these short listed biomarkers was abnormal. 89 patients (3 or 4
biomarkers abnormal) have been deﬁnitely included to progress into
theMultidose Trial, and a further 46 (1 or 2 biomarkers abnormal) are
awaiting the ﬁnal primary outcome selection. The Run-in study has,
therefore, been able to a) select a cohort of ‘optimal’ patients in which
to assess gene therapy and b) provide an indication of which may be
the more useful biomarkers to use in phase IIB clinical trials of novel
therapeutic agents.
S19 REAL TIME PCR IN THE IDENTIFICATION AND
MANAGEMENT OF ASPERGILLUS IN CF
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Adult CF Unit, Manchester, UK
Purpose The reported prevalence of Aspergillus fumigatus in CF
sputum varies widely from 12 to 57%. While patients with ABPA are
routinely treated with antifungals, it is not know whether colonised
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